Sets the scene for a messenger RNA production facility in Canada
Moderna announced a memorandum of understanding (MoU) with the Canadian government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada. The MoU is intended to not only support Canada with direct access to rapid pandemic response capabilities, but to also provide the nation with access to the biotech company’s vaccines that are developed to combat respiratory viruses, such as Covid-19, seasonal influenza and respiratory syncytial virus (RSV), along with other potential vaccines.
“We are excited to expand our presence and continue our long-term collaboration with Canada,” says Patricia Gauthier, Moderna’s Canadian general manager. “With our industry-leading mRNA technology platform and rapid drug development capabilities, we look forward to being an active participant in Canada’s robust life sciences ecosystem.”
Moderna also recently made headlines after announcing that its Spikevax Covid vaccine presented 93% efficacy following administration of the second dose (via the Phase 3 COVE study).